 BOULDER, Colo., Aug. 03, 2020 GLOBE NEWSWIRE -- Brickell Biotech, Inc. Brickell Nasdaq: BBI, a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that it will report its financial results for the second quarter ended June 30, 2020, after the market close on Wednesday, August 12, 2020. Brickells management will host a conference call and webcast at 4:30pm ET to discuss the financial results and recent corporate highlights.To access the call, please dial 877-705-6003 in the U.S. or 201-493-6725 outside the U.S. and provide the conference ID number: 13706625. To access the live webcast, please go to the investors section of Brickells website at Following the live webcast, an archived version of the call will be available on the website.About Brickell Bio Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickells pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickells executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed andor launched successful products, including several that were first-in-class andor achieved iconic status, such as Cialis, Taltz, Gemzar, Prozac, Cymbalta and Juvederm. Brickells strategy is to leverage this experience to in-license, acquire, develop, and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit Investor Contact: 